JPRN-jRCT2080222369未知1 期
Extension study following the phase I/II clinical study of CT-P13 in the patients with rheumatoid arthritis
ippon Kayaku Co., Ltd.0 个研究点开始时间: 2014年1月16日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Patients who have completed final observation after 54-week administration in the phase I/II clinical study and whose symptoms are stable.
- •(2) Patients for whom administration of CT-P13 is deemed appropriate as of the end of final observation after 54-week administration in the phase I/II clinical study.
排除标准
- 未提供
研究者
相似试验
未知
4 期
Extension study following the phase I/II clinical study of CT-P13 in the patients with rheumatoid arthritisRheumatoid arthritisJPRN-jRCT1080222652ippon Kayaku Co., Ltd.
招募中
1 期
ong-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of RP-L102Fanconi anemia subtype A (FA-A)MedDRA version: 20.0Level: LLTClassification code: 10055206Term: Fanconi's anemia Class: 10010331CTIS2022-501082-52-00Rocket Pharmaceuticals Inc.14
进行中（未招募）
1 期
A study to test how well patients with plaque psoriasis tolerate BI 730357 over a longer period and how effective it isPlaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2018-003487-31-DEBoehringer Ingelheim Pharma GmbH & Co. KG180
进行中（未招募）
1 期
A follow-up study in patients with moderate to severe active ulcerative colitis.Moderate to severe Ulcerative Colitis.MedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856EUCTR2017-003284-35-PLABIVAX30
进行中（未招募）
1 期
A follow-up study in patients with moderate to severe active ulcerative colitis.Moderate to severe Ulcerative Colitis.MedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856EUCTR2017-003284-35-HUABIVAX30